Jobs

Twelve is a carbon transformation company focused on converting CO2 into essential products through innovative electrochemical technology. Their flagship products include E-Jet® SAF and CO2Made® materials, which are designed to eliminate industrial emissions and provide sustainable alternatives to fossil fuels. By leveraging their proprietary Opus™ system, Twelve aims to revolutionize the production of hydrocarbons, making them from air instead of oil. The company is positioned at the forefront of the sustainable fuels market, partnering with major brands like Alaska Airlines and Mercedes-Benz to drive the transition to a fossil-free future. With a strong commitment to industrial innovation, Twelve is well-positioned to capture significant market share in the growing demand for sustainable materials and fuels.

Modern Meadow is a pioneer in sustainable materials, creating innovative biomaterials like BIO-VERA® that replace petrochemical and animal-derived inputs. Their technology platform allows seamless integration into existing manufacturing processes, enabling industries such as fashion, footwear, and automotive to produce high-quality, sustainable products. With over 250,000 handbags and jackets produced and 11 global partners, Modern Meadow is positioned as a leader in bioinnovation, driving sustainability and performance in material production.

Zymo Chem is a biotech company focused on manufacturing bio-based products using proprietary Carbon Conserving (C2) microbes. Their innovative platform converts renewable feedstocks into high-value materials, targeting industries such as hygiene, textiles, plastics, and coatings. By promoting a circular economy and reducing reliance on fossil fuels, Zymo Chem aims to transform the sustainability landscape, positioning itself as a leader in the bio-manufacturing sector. The company has gained traction with significant funding and recognition, including a recent $1.57M award from the U.S. Department of Defense, highlighting its commitment to environmental impact and innovation.

Cytovale is a medical technology company that has developed Intelli Sep, an FDA-cleared diagnostic tool for early sepsis detection. This innovative solution risk-stratifies patients based on their likelihood of developing sepsis within three days, providing results in approximately eight minutes. By analyzing the immune response through the biomechanical properties of white blood cells, Intelli Sep offers a highly sensitive measure for identifying sepsis, addressing a critical gap in timely diagnosis and treatment. The company aims to improve patient outcomes and operational efficiencies in emergency departments, positioning itself as a leader in sepsis diagnostics.

Parallel Bio is pioneering the use of immune organoids and AI to revolutionize drug discovery, focusing on immunotherapies that leverage the human immune system. By creating in-vitro models that accurately replicate human immune responses, the company aims to eliminate the inefficiencies and ethical concerns associated with traditional animal testing. Their platform allows for rapid, cost-effective development of therapies that are designed to work in humans from the outset, significantly reducing the time and financial burden typically associated with drug development. With a strong emphasis on scalability and population diversity, Parallel Bio is positioned to transform the landscape of immunotherapy and address previously untreatable diseases, collaborating with major pharmaceutical and biotech companies to bring innovative solutions to market.

Cell Chorus is a dynamic single-cell analysis company that leverages its TIMING™ platform to provide high-throughput, real-time evaluation of individual cell behaviors, including activation, movement, and interactions. This technology is particularly valuable for biopharmaceutical companies, enabling them to identify promising candidates for clinical trials and enhance the understanding of immune responses. By integrating artificial intelligence with advanced microscopy, Cell Chorus differentiates itself in the market, offering insights that traditional assays cannot provide. The company has established a strong position by serving top-tier biopharmaceutical clients and is backed by patents and significant funding, indicating robust traction and growth potential in the life sciences sector.

Strateos automates chemistry, biology, and tissue analysis into closed-loop robotic labs that accelerate drug discovery programs. Through a combination of best-in-class robotics and control systems, advanced software for imaging and analytics, and remote cloud laboratories, they enable pharmaceutical partners to more rapidly and efficiently discover new drug candidates. Born of a merger between Transcriptic and 3Scan, Strateos combines the strengths of those companies to amplify their impact and accelerate drug discovery. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combined automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development. By expressing life science methods as data, infrastructure virtualization will become possible. ''Science-as-a-Service'' will power the next generation of discovery, driven by huge efficiencies of both time and money. Transcriptic was founded in 2012 to create a better way to get lab work done. Tired of spending endless hours at the bench pretending to be slow, error-prone robots, they set out to build a modern solution to the day-to-day process of wet lab biology. Drawing on deep computer science and electrical engineering backgrounds in addition to life science, Strateos was born: a meticulously optimized, technology-enabled remote lab. Using state-of-the-art automation and control technology, and an emphasis on user experience and usability, they are working on building a stark contrast to the long, complicated sales process, high prices, and slow turnarounds of traditional CROs. They are working hard to build a great company that can be a true partner for your lab for a long time, progressively enabling ever greater levels of productivity and efficiency. They are scientists building for scientists.

Copernic Catalysts designs innovative catalysts for zero-carbon chemicals and e-fuels, focusing on cost-effective and scalable solutions. Their technology enhances the design of heterogeneous catalysts, crucial for the chemical industry, by utilizing advanced scientific computing tools. With a commitment to sustainability, Copernic aims to transform the chemical industry by providing economically viable solutions that align with existing infrastructure, thereby accelerating the development of catalysts for a sustainable future.

Immusoft is a biotechnology company that leads in developing B cells as biofactories for therapeutic protein delivery. Their innovative approach, Immune System Programming (ISP™), involves programming a patient's B cells to produce personalized protein therapeutics. This technology allows for the expansion of these programmed B cells into plasma cells that can manufacture therapeutic proteins for extended periods. Immusoft's focus on rare diseases positions it uniquely in the biotechnology market, with promising early data from clinical trials indicating significant potential for their lead candidate, ISP-001, in treating Mucopolysaccharidosis type I (MPS I).

Surf Bio is a preclinical biopharmaceutical company founded in 2021, focused on transforming the delivery of biologics through its innovative Surf Snap Shot™ technology. This technology allows for the rapid administration of high concentrations of monoclonal antibodies via subcutaneous injection, significantly improving patient experience by enabling at-home self-administration instead of lengthy IV infusions. Surf Bio's proprietary polymer formulation enhances the accessibility and convenience of biologic therapies, positioning the company as a leader in the biopharmaceutical delivery space. With a strong team of experienced professionals and ongoing collaborations with major pharmaceutical companies, Surf Bio is well-positioned to make a significant impact in the market.

Noetik is an AI-native biotechnology company focused on leveraging advanced machine learning methods to discover and develop precision cancer immunotherapies. By combining self-supervised learning with large-scale human multimodal data, Noetik aims to create foundation models for cell and tissue biology that drive therapeutic development. The company differentiates itself through its innovative approach to drug discovery, addressing the complexities of tumor-immune interactions, and is positioned to make significant impacts in the oncology space.

Phantom Neuro is a neurotechnology company spun out of Johns Hopkins University, focused on creating minimally invasive muscle-machine interfaces for controlling robotic prosthetic limbs and exoskeletons. Their innovative technology aims to enhance the lives of individuals with limb differences by providing lifelike control of robotic systems. With a strong team of experts in neuroscience, surgery, and robotics, Phantom Neuro is positioned at the forefront of medical innovation, aiming to bridge the gap between modern robotics and human capability. The company has raised $9.5 million in seed funding, indicating strong investor interest and potential for growth in the neurotechnology market.